Vaccines for tuberculosis: Novel concepts and recent progress

Clinical Microbiology Reviews

Volumn 18, Issue 4, 2005, Pages 687-702

  Doherty, T Mark ^a   Andersen, Peter ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIGEN 85B; AS 2; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIAL TOXIN LTK63; BCG VACCINE; CALCIUM PHOSPHATE; CATIONIC SURFACTANT; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; HSPX ANTIGEN; HYBRID PROTEIN; IC 31; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; ISCOM; LIPOVAC; LTK 63; LYSOZYME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MVA 85A; MYCOBACTERIUM ANTIGEN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; OM 174; PHOSPHORYL LIPID A; QUIL A; RECOMBINANT VACCINE; RECOMBINANT VACCINIA VIRUS VACCINE; TUBERCULOSIS VACCINE 72F; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME;

ANTIGEN SPECIFICITY; BACTERIAL GENE; BCG VACCINATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENOMICS; HOST PATHOGEN INTERACTION; HSPX GENE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOPATHOLOGY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOCYTOSIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TUBERCULOSIS; VIRUS INFECTION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BCG VACCINE; CYTOKINES; IMMUNIZATION, SECONDARY; MYCOBACTERIUM TUBERCULOSIS; TH1 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; VACCINIA VIRUS;

EID: 27144483079     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.18.4.687-702.2005     Document Type: Review

References (195)

1. Aaron, L., D. Saadoun, I. Calatroni, O. Launay, N. Memain, V. Vincent, G. Marchai, B. Dupont, O. Bouchaud, D. Valeyre, and O. Lortholary. 2004. Tuberculosis in HIV-infected patients: a comprehensive review. Clin. Microbiol. Infect. 10:388-398.
2. Agger, E. M., and P. Andersen. 2001. Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 19:2298-2302.
3. Anonymous 1999. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J. Med. Res. 110:56-69.
4. Anonymous 2005. Global tuberculosis control - surveillance, planning, financing W.H.O./HTMTB/2005. World Health Organization, Geneva, Switzerland.
5. Arias, M., M. Rojas, J. Zabaleta, J. I. Rodriguez, S. C. Paris, L. F. Barrera, and L. F. Garcia. 1997. Inhibition of virulent Mycobacterium tuberculosis by Bcg(r) and Bcg(s) macrophages correlates with nitric oxide production. J Infect. Dis. 176:1552-1558.
6. Aronson, N. E., M. Santosham, G. W. Comstock, R. S. Howard, L. H. Moulton, E. R. Rhoades, and L. H. Harrison. 2004. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA. 291:2086-2091.
7. Aucouturier, J., L. Dupuis, S. Deville, S. Ascarateil, and V. Ganne. 2002. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1:111-118.
8. Baily, G. V. 1980. Tuberculosis prevention Trial, Madras. Indian J. Med. Res. 72(Suppl.):1-74.
9. Behar, S. M., C. C. Dascher, M. J. Grusby, C. R. Wang, and M. B. Brenner. 1999. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J. Exp. Med. 189:1973-1980.
10. Behr, M. A. 2001. Correlation between BCG genomics and protective efficacy. Scand. J. Infect. Dis. 33:249-252.
11. Brandt, L., J. Feino Cunha, A. Weinreich Olsen, B. Chilima, P. Hirsch, R. Appelberg, and P. Andersen. 2002. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70:672-678.
12. Brandt, L., Y. A. Skeiky, M. R. Alderson, Y. Lobet, W. Dalemans, O. C. Turner, R. J. Basaraba, A. A. Izzo, T. M. Lasco, P. L. Chapman, S. G. Reed, and I. M. Orme. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72:6622-6632.
13. Brennan, P. J. 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinburgh) 83:91-97.
14. Brewer, J. M., M. Conacher, C. A. Hunter, M. Mohrs, F. Brombacher, and J. Alexander. 1999. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 163:6448-6454.
15. Brewer, T. F. 2000. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 31(Suppl. 3): S64-67.
16. Brosch, R., S. V. Gordon, M. Marmiesse, P. Brodin, C. Buchrieser, K. Eiglmeier, T. Garnier, C. Gutierrez, G. Hewinson, K. Kremer, L. M. Parsons, A. S. Pym, S. Samper, D. van Soolingen, and S. T. Cole. 2002. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc. Natl. Acad. Sci. USA 99:3684-3689.
17. Brosch, R., A. S. Pym, S. V. Gordon, and S. T. Cole. 2001. The evolution of mycobacterial pathogenicity: clues from comparative genomics. Trends Microbiol. 9:452-458.
18. Brown, N., M. Jacobs, S. K. Parida, T. Botha, A. Santos, L. Pick, B. Gicquel, M. Jackson, V. Quesniaux, and B. Ryffel. 2005. Reduced local growth and spread but preserved pathogenicity of a ΔpurC Mycobacterium tuberculosis auxotrophic mutant in gamma interferon receptor-deficient mice after aerosol infection. Infect. Immun. 73:666-670.
19. Buddle, B. M., B. J. Wards, F. E. Aldwell, D. M. Collins, and G. W. de Lisle. 2002. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 20:1126-1133.
20. Calmette, A., and H. Plotz. 1929. Protective inoculation against tuberculosis with BCG. Am. Rev. Tuberc. 19:567-572.
21. Campos, J. M., J. P. Simonetti, M. V. Pone, L. A. Carvalho, A. C. Pereira, and J. R. Garrido. 1996. Disseminated Bacillus Calmette-Guerin infection in HIV-infected children: case report and review. Pediatr. AIDS HIV Infect. 7:429-432.
22. Caruso, A. M., N. Serbina, E. Klein, K. Triebold, B. R. Bloom, and J. L. Flynn. 1999. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J. Immunol. 162:5407-5416.
23. Chua, J., and V. Deretic. 2004. Mycobacterium tuberculosis reprograms waves of phosphatidylinositol 3-phosphate on phagosomal organelles. J. Biol. Chem. 279:36982-36992.
24. Chua, J., I. Vergne, S. Master, and V. Deretic. 2004. A tale of two lipids: Mycobacterium tuberculosis phagosome maturation arrest. Curr. Opin. Microbiol. 7:71-77.
25. Colditz, G. A., C. S. Berkey, F. Mosteller, T. F. Brewer, M. E. Wilson, E. Hurdick, and H. V. Fineberg. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96:29-35.
26. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
27. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry, 3rd, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. Mclean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M.-A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrel. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544.
28. Comstock, G. W., S. F. Woolpert, and V. T. Livesay. 1976. Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. Public Health Rep. 91:276-280.
29. Conradt, P., J. Hess, and S. H. Kaufmann. 1999. Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin. Microbes Infect. 1:753-764.
30. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178:2243-2247.
31. Dascher, C. C., and M. B. Brenner. 2003. CD1 antigen presentation and infectious disease. Contrib. Microbiol. 10:164-182.
32. de Boer, A. S., and D. van Soolingen. 2000. Recurrent tuberculosis due to exogenous reinfection. N. Engl. J. Med. 342:1050-1051.
33. de Jong, R., F. Altare, I. A. Haagen, D. G. Elferink, T. Boer, P. J. van Breda Vriesman, P. J. Kabel, J. M. Draaisma, J. T. van Dissel, F. P. Kroon, J. L. Casanova, and T. H. Ottenhoff. 1998. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280:1435-1438.
34. de Lisle, G. W., B. J. Wards, B. M. Buddle, and D. M. Collins. 2005. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium. Tuberculosis (Edinburgh) 85:73-79.
35. Delogu, G., and M. J. Brennan. 2001. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect. Immun. 69:5606-5611.
36. Demissie, A., M. Abebe, A. Aseffa, G. Rook, H. Fletcher, A. Zumla, K. Weldingh, I. Brock, P. Andersen, and T. M. Doherty. 2004. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J. Immunol. 172:6938-6943.
37. Dieli, F., N. Caccamo, S. Meraviglia, J. Ivanyi, G. Sireci, C. T. Bonanno, V. Ferlazzo, C. La Mendola, and A. Salerno. 2004. Reciprocal stimulation of gammadelta T cells and dendritic cells during the anti-mycobacterial immune response. Eur. J. Immunol. 34:3227-3235.
38. Dieli, F., J. Ivanyi, P. Marsh, A. Williams, I. Naylor, G. Sireci, N. Caccamo, C. Di Sano, and A. Salerno. 2003. Characterization of lung gamma delta T cells following intranasal infection with Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 170:463-469.
39. Dietrich, J., C. Aagaard, R. Leah, A. W. Olsen, A. Stryhn, T. M. Doherty, and P. Andersen. 2005. Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy. J. Immunol. 174:6332-6339.
40. Doherty, T. M., A. Demissie, J. Olobo, D. Wolday, S. Britton, T. Eguale, P. Ravn, and P. Andersen. 2002. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J. Clin. Microbiol. 40:704-706.
41. Doherty, T. M., A. W. Olsen, L. van Pinxteren, and P. Andersen. 2002. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 70:3111-3121.
42. Doherty, T. M., A. W. Olsen, J. Weischenfeldt, K. Huygen, S. D'Souza, T. K. Kondratieva, V. V. Yeremeev, A. S. Apt, B. Raupach, L. Grode, S. H. E. Kaufmann, and P. Andersen. 2004. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J. Infect. Dis. In Press.
43. Downing, K. J., V. V. Mischenko, M. O. Shleeva, D. I. Young, M. Young, A. S. Kaprelyants, A. S. Apt, and V. Mizrahi. 2005. Mutants of Mycobacterium tuberculosis lacking three of the five rpf-like genes are defective for growth in vivo and for resuscitation in vitro. Infect. Immun. 73:3038-3043.
44. Espitia, C., J. P. Laclette, M. Mondragon-Palomino, A. Amador, J. Campuzano, A. Martens, M. Singh, R. Cicero, Y. Zhang, and C. Moreno. 1999. The PE-PGRS glycine-rich proteins of Mycobacterium tuberculosis: a new family of fibronectin-binding proteins? Microbiology. 145:3487-3495.
45. Feng, C. G., C. M. Collazo-Custodio, M. Eckhaus, S. Hieny, Y. Belkaid, K. Elkins, D. Jankovic, G. A. Taylor, and A. Sher. 2004. Mice deficient in LRG-47 display increased susceptibility to mycobacterial infection associated with the induction of lymphopenia. J. Immunol. 172:1163-1168.
46. Fine, P. E. 1998. Vaccines, genes and trials. Novartis Found Symp. 217:57-69; discussion 69-72.
47. Fine, P. E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345.
48. Fletcher, H. A., P. Owiafe, D. Jeffries, P. Hill, G. A. Rook, A. Zumla, T. M. Doherty, and R. H. Brookes. 2004. Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology. 112:669-673.
49. Fortune, S. M., A. Solache, A. Jaeger, P. J. Hill, J. T. Belisle, B. R. Bloom, E. J. Rubin, and J. D. Ernst. 2004. Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J. Immunol. 172:6272-6280.
50. Fouts, T. R., A. L. DeVico, D. Y. Onyabe, M. T. Shata, K. C. Bagley, G. K. Lewis, and D. M. Hone. 2003. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol. Med. Microbiol. 37:129-134.
51. Francis, J. 1956. Natural and experimental tuberculosis in monkeys; with observations on immunization and chemotherapy. J Comp. Pathol. 66:123-135.
52. Fratti, R. A., J. Chua, I. Vergne, and V. Deretic. 2003. Mycobacterium tuberculosis glycosylated phosphatidylinositol causes phagosome maturation arrest. Proc. Natl. Acad. Sci. USA 100:5437-5442.
53. Fulton, S. A., S. M. Reba, R. K. Pai, M. Pennini, M. Torres, C. V. Harding, and W. H. Boom. 2004. Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect. Immun. 72:2101-2110.
54. Geytenbeek, T. B., S. J. Van Vliet, E. A. Koppel, M. Sanchez-Hernandez, C. M. Vandenbroucke-Grauls, B. Appelmelk, and Y. Van Kooyk. 2003. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp. Med. 197:7-17.
55. Gonzalez-Juarrero, M., O. C. Turner, J. Turner, P. Marietta, J. V. Brooks, and I. M. Orme. 2001. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 69:1722-1728.
56. Goonetilleke, N. P., H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. Hill. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171:1602-1609.
57. Grode, L., M. Kursar, J. Fensterle, S. H. Kaufmann, and J. Hess. 2002. Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guerin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy. J. Immunol. 168:1869-1876.
58. Gupta, R. K., and G. R. Siber. 1995. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13:1263-1276.
59. Harboe, M., T. Oettinger, H. G. Wiker, I. Rosenkrands, and P. Andersen. 1996. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect. Immun. 64:16-22.
60. Hart, P. D. 1967. Efficacy and applicability of mass BCG vaccination in tuberculosis control. Br. Med. J. 1:587-592.
61. Hart, P. D., and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med. J. 2:293-295.
62. He, Q., A. R. Mitchell, S. L. Johnson, C. Wagner-Bartak, T. Morcol, and S. J. Bell. 2000. Calcium phosphate nanoparticle adjuvant. Clin. Diagn. Lab Immunol. 7:899-903.
63. Hogarth, P. J., K. J. Jahans, R. Hecker, R. G. Hewinson, and M. A. Chambers. 2003. Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. Vaccine 21:977-982.
64. Holten-Andersen, L., T. M. Doherty, K. S. Korsholm, and P. Andersen. 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun. 72:1608-1617.
65. Honer zu Bentrup, K., and D. G. Russell. 2001. Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol. 9:597-605.
66. Hori, S., and S. Sakaguchi. 2004. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 6:745-751.
67. Horwitz, M. A., and G. Harth. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71:1672-1679.
68. Hovav, A. H., J. Mullerad, L. Davidovitch, Y. Fishman, F. Bigi, A. Cataldi, and H. Bercovier. 2003. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect. Immun. 71:3146-3154.
69. Hsu, T., S. M. Hingley-Wilson, B. Chen, M. Chen, A. Z. Dal, P. M. Morin, C. B. Marks, J. Padiyar, C. Goulding, M. Gingery, D. Eisenberg, R. G. Russell, S. C. Derrick, F. M. Collins, S. L. Morris, C. H. King, and W. R. Jacobs, Jr. 2003. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc. Natl. Acad. Sci. USA 100:12420-12425.
70. Huckriede, A., L. Bungener, T. Daemen, and J. Wilschut. 2003. Influenza virosomes in vaccine development. Methods Enzymol. 373:74-91.
71. Indrigo, J., R. L. Hunter, Jr., and J. K. Actor. 2003. Cord factor trehalose 6,6′-dimycolate (TDM) mediates trafficking events during mycobacterial infection of murine macrophages. Microbiology. 149:2049-2059.
72. Iseman, M. D. 2002. Tuberculosis therapy: past, present and future. Eur. Respir. J. Suppl. 36:87s-94s.
73. Jalapathy, K. V., C. Prabha, and S. D. Das. 2004. Correlates of protective immune response in tuberculous pleuritis. FEMS Immunol. Med. Microbiol. 40:139-145.
74. Jimenez-Martinez, M. C., M. Linares, R. Baez, L. F. Montano, S. Martinez-Cairo, P. Gorocica, R. Chavez, E. Zenteno, and R. Lascurain. 2004. Intracellular expression of interleukin-4 and interferon-gamma by a Mycobacterium tuberculosis antigen-stimulated CD4+ CD57+ T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology. 111:100-106.
75. Jo, E. K., J. K. Park, and H. M. Dockrell. 2003. Dynamics of cytokine generation in patients with active pulmonary tuberculosis. Curr. Opin. Infect. Dis. 16:205-210.
76. Jouanguy, E., F. Altare, S. Lamhamedi, P. Revy, J. F. Emile, M. Newport, M. Levin, S. Blanche, E. Seboun, A. Fischer, and J. L. Casanova. 1996. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335:1956-1961.
77. Kamath, A. T., U. Fruth, M. J. Brennan, R. Dobbelaer, P. Hubrechts, M. M. Ho, R. E. Mayner, J. Thole, K. B. Walker, M. Liu, and P. H. Lambert. 2005. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23:3753-3761.
78. Kaufmann, S. H., and C. H. Ladel. 1994. Role of T-cell subsets in immunity against intracellular bacteria: experimental infections of knock-out mice with Listeria monocytogenes and Mycobacterium bovis BCG. Immunobiology. 191:509-519.
79. Kelley, V. A., and J. S. Schorey. 2003. Mycobacterium's arrest of phagosome maturation in macrophages requires Rab5 activity and accessibility to iron. Mol. Biol Cell. 14:3366-3377.
80. Koch, R. 1982. Classics in infectious diseases. The etiology of tuberculosis: Robert Koch. Berlin, Germany 1882. Rev. Infect. Dis. 4:1270-1274.
81. Korf, J., A. Stoltz, J. Verschoor, P. De Baetselier, and J. Grooten. 2005. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur. J. Immunol. 35:890-900.
82. Ladel, C. H., C. Blum, A. Dreher, K. Reifenberg, and S. H. Kaufmann. 1995. Protective role of gamma/delta T cells and alpha/beta T cells in tuberculosis. Eur. J. Immunol. 25:2877-2881.
83. Ladel, C. H., S. Daugelat, and S. H. Kaufmann. 1995. Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur. J. Immunol. 25:377-384.
84. Ladel, C. H., J. Hess, S. Daugelat, P. Mombaerts, S. Tonegawa, and S. H. Kaufmann. 1995. Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against Mycobacterium bovis bacillus Calmette Guerin: studies with T-cell receptor-deficient mutant mice. Eur. J. Immunol. 25:838-846.
85. Lalvani, A., P. Nagvenkar, Z. Udwadia, A. A. Pathan, K. A. Wilkinson, J. S. Shastri, K. Ewer, A. V. Hill, A. Mehta, and C. Rodrigues. 2001. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J. Infect. Dis. 183:469-477.
86. Lalvani, A., A. A. Pathan, H. Durkan, K. A. Wilkinson, A. Whelan, J. J. Deeks, W. H. Reece, M. Latif, G. Pasvol, and A. V. Hill. 2001. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357:2017-2021.
87. Lalvani, A., A. A. Pathan, H. McShane, R. J. Wilkinson, M. Latif, C. P. Conlon, G. Pasvol, and A. V. Hill. 2001. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am. J. Respir. Crit. Care Med. 163:824-828.
88. Lee, R. E., P. J. Brennan, and G. S. Besra. 1996. Mycobacterium tuberculosis cell envelope. Curr. Top. Microbiol. Immunol. 215:1-27.
89. Leung, C. C., C. M. Tam, S. L. Chan, M. Chan-Yeung, C. K. Chan, and K. C. Chang. 2001. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int J. Tuberc. Lung Dis. 5:717-723.
90. Lienhardt, C., A. Azzurri, A. Amedei, K. Fielding, J. Sillah, O. Y. Sow, B. Bah, M. Benagiano, A. Diallo, R. Manetti, K. Manneh, P. Gustafson, S. Bennett, M. M. D'Elios, K. McAdam, and G. Del Prete. 2002. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur. J. Immunol. 32:1605-1613.
91. Lillebaek, T., A. Dirksen, I. Baess, B. Strunge, V. O. Thomsen, and A. B. Andersen. 2002. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J. Infect. Dis. 185:401-404.
92. Lindblad, E. B., M. J. Elhay, R. Silva, R. Appelberg, and P. Andersen. 1997. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65:623-629.
93. Lingnau, K., A. Egyed, C. Schellack, F. Mattner, M. Buschle, and W. Schmidt. 2002. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. Vaccine 20:3498-3508.
94. Long, R., and M. Gardam. 2003. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. Cmaj. 168:1153-1156.
95. Lowrie, D. B., R. E. Tascon, V. L. Bonato, V. M. Lima, L. H. Faccioli, E. Stavropoulos, M. J. Colston, R. G. Hewinson, K. Moelling, and C. L. Silva. 1999. Therapy of tuberculosis in mice by DNA vaccination. Nature 400:269-271.
96. Lozes, E., O. Denis, A. Drowart, F. Jurion, K. Palfliet, A. Vanonckelen, J. De Bruyn, M. De Cock, J. P. Van Vooren, and K. Huygen. 1997. Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-Group. Scand. J. Immunol. 46:16-26.
97. Lyashchenko, K., A. O. Whelan, R. Greenwald, J. M. Pollock, P. Andersen, R. G. Hewinson, and H. M. Vordermeier. 2004. Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis. Infect. Immun. 72:2462-2467.
98. MacMicking, J. D., G. A. Taylor, and J. D. McKinney. 2003. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 302:654-659.
99. Majlessi, L., P. Brodin, R. Brosch, M. J. Rojas, H. Khun, M. Huerre, S. T. Cole, and C. Ledere. 2005. Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. J. Immunol. 174:3570-3579.
100. Malik, Z. A., S. S. Iyer, and D. J. Kusner. 2001. Mycobacterium tuberculosis phagosomes exhibit altered calmodulin-dependent signal transduction: contribution to inhibition of phagosome-lysosome fusion and intracellular survival in human macrophages. J. Immunol. 166:3392-3401.
101. Manca, C., M. B. Reed, S. Freeman, B. Mathema, B. Kreiswirth, C. E. Barry, 3rd, and G. Kaplan. 2004. Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect. Immun. 72:5511-5514.
102. Marchant, A., A. Amedei, A. Azzurri, J. Vekemans, M. Benagiano, C. Tamburini, C. Lienhardt, T. Corrah, K. P. McAdam, S. Romagnani, M. M. D'Elios, and G. Del Prete. 2001. Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. Am. J. Respir. Cell Mol. Biol. 24:187-194.
103. Mattner, F., J. K. Fleitmann, K. Lingnau, W. Schmidt, A. Egyed, J. Fritz, W. Zauner, B. Wittmann, I. Gorny, M. Berger, H. Kirlappos, A. Otava, M. L. Birnstiel, and M. Buschle. 2002. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res. 62:1477-1480.
104. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240-1244.
105. Means, T. K., S. Wang, E. Lien, A. Yoshimura, D. T. Golenbock, and M. J. Fenton. 1999. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J. Immunol. 163:3920-3927.
106. Mehrotra, J., and W. R. Bishai. 2001. Regulation of virulence genes in Mycobacterium tuberculosis. Int. J. Med. Microbiol. 291:171-182.
107. Meraldi, V., R. Audran, J. F. Romero, V. Brossard, J. Bauer, J. A. Lopez, and G. Corradin. 2003. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 21:2485-2491.
108. Mollenkopf, H. J., M. Kursar, and S. H. Kaufmann. 2004. Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guerin induce equal protection. J Infect. Dis. 190:588-597.
109. Morein, B., M. Villacres-Eriksson, J. Ekstrom, K. Hu, S. Behboudi, and K. Lovgren-Bengtsson. 1999. ISCOM: a delivery system for neonates and for mucosal administration. Adv. Vet. Med. 41:405-413.
110. Morita, C. T., Y. Tanaka, B. R. Bloom, and M. B. Brenner. 1996. Direct presentation of non-peptide prenyl pyrophosphate antigens to human gamma delta T cells. Res. Immunol. 147:347-353.
111. Nathan, C., and M. U. Shiloh. 2000. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. USA 97:8841-8848.
112. Noss, E. H., R. K. Pai, T. J. Sellati, J. D. Radolf, J. Belisle, D. T. Golenbock, W. H. Boom, and C. V. Harding. 2001. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J. Immunol. 167:910-918.
113. Nuzzo, I., M. Galdiero, C. Bentivoglio, R. Galdiero, and C. Romano Carratelli. 2002. Apoptosis modulation by mycolic acid, tuberculostearic acid and trehalose 6,6′-dimycolate. J. Infect. 44:229-235.
114. O'Regan, A., and M. Joyce-Brady. 2001. Latent tuberculosis may persist for over 40 years. Br. Med. J. 323:635.
115. Oiso, R., N. Fujiwara, H. Yamagami, S. Maeda, S. Matsumoto, S. Nakamura, N. Oshitani, T. Matsumoto, T. Arakawa, and K. Kobayashi. 2005. Mycobacterial trehalose 6,6′-dimycolate preferentially induces type 1 helper T-cell responses through signal transducer and activator of transcription 4 protein. Microb. Pathog. 39:35-43.
116. Olobo, J. O., M. Geletu, A. Demissie, T. Eguale, K. Hiwot, G. Aderaye, and S. Britton. 2001. Circulating TNF-alpha. TGF-beta, and IL-10 in tuberculosis patients and healthy contacts. Scand. J. Immunol. 53:85-91.
117. Olsen, A. W., A. Williams, L. M. Okkels, G. Hatch, and P. Andersen. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72:6148-6150.
118. Ordway, D. J., L. Costa, M. Martins, H. Silveira, L. Amaral, M. J. Arroz, F. A. Ventura, and H. M. Dockrell. 2004. Increased interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J. Infect. Dis. 190:756-766.
119. Ordway, D. J., L. Pinto, L. Costa, M. Martins, C. Leandro, M. Viveiros, L. Amaral, M. J. Arroz, F. A. Ventura, and H. M. Dockrell. 2005. Gamma delta T-cell responses associated with the development of tuberculosis in health care workers. FEMS Immunol. Med. Microbiol. 43:339-350.
120. Pai, R. K., M. E. Pennini, A. A. Tobian, D. H. Canaday, W. H. Boom, and C. V. Harding. 2004. Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect. Immun. 72:6603-6614.
121. Peppoloni, S., P. Ruggiero, M. Contorni, M. Morandi, M. Pizza, R. Rappuoli, A. Podda, and G. Del Giudice. 2003. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2:285-293.
122. Pethe, K., D. L. Swenson, S. Alonso, J. Anderson, C. Wang, and D. G. Russell. 2004. Isolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturation. Proc. Natl. Acad. Sci. USA 101:13642-13647.
123. Podda, A., and G. Del Giudice. 2003. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2:197-203.
124. Pym, A. S., P. Brodin, L. Majlessi, R. Brosch, C. Demangel, A. Williams, K. E. Griffiths, G. Marchal, C. Leclerc, and S. T. Cole. 2003. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9:533-539.
125. Quesniaux, V., C. Fremond, M. Jacobs, S. Parida, D. Nicolle, V. Yeremeev, F. Bihl, F. Erard, T. Botha, M. Drennan, M. N. Soler, M. Le Bert, B. Schnyder, and B. Ryffel. 2004. Toll-like receptor pathways in the immune responses to mycobacteria. Microbes Infect. 6:946-959.
126. Rahemtulla, A., W. P. Fung-Leung, M. W. Schilham, T. M. Kundig, S. R. Sambhara, A. Narendran, A. Arabian, A. Wakeham, C. J. Paige, R. M. Zinkernagel, et al. 1991. Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353:180-184.
127. Rao, V., N. Dhar, and A. K. Tyagi. 2003. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette-Guerin. Scand. J. Immunol. 58:449-461.
128. Ravn, P., A. Demissie, T. Eguale, H. Wondwosson, D. Lein, H. A. Amoudy, A. S. Mustafa, A. K. Jensen, A. Holm, I. Rosenkrands, F. Oftung, J. Olobo, F. von Reyn, and P. Andersen. 1999. Hum. T-cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179:637-645.
129. 128a. Raynaud, C., C. Guilhot, J. Rauzier, Y. Bordat, V. Pelicic, R. Manganelli, I. Smith, B. Gicquel, and M. Jackson. 2002. Phospholipases C are involved in the virulence of Mycobacterium tuberculosis. Mol. Microbiol. 45:203-217.
130. Reed, M. B., P. Domenech, C. Manca, H. Su, A. K. Barczak, B. N. Kreiswirth, G. Kaplan, and C. E. Barry 3rd. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87.
131. Rolph, M. S., B. Raupach, H. H. Kobernick, H. L. Collins, B. Perarnau, F. A. Limonnier, and S. H. Kaufmann. 2001. MHC class Ia-restricted T cells partially account for beta2-microglobulin-dependent resistance to Mycobacterium tuberculosis. Eur. J. Immunol. 31:1944-1949.
132. Rook, G. A., and J. L. Stanford. 1996. The Koch phenomenon and the immunopathology of tuberculosis. Curr. Top. Microbiol. Immunol. 215:239-262.
133. Roura-Mir, C., and D. B. Moody. 2003. Sorting out self and microbial lipid antigens for CD1. Microbes Infect. 5:1137-1148.
134. Russell, D. G. 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell. Biol. 2:569-577.
135. Russell, D. G., J. Dant, and S. Sturgill-Koszycki. 1996. Mycobacterium avium- and Mycobacterium tuberculosis-containing vacuoles are dynamic, fusion-competent vesicles that are accessible to glycosphingolipids from the host cell plasmalemma. J. Immunol. 156:4764-4773.
136. Ryll, R., Y. Kumazawa, and I. Yano. 2001. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids-a review. Microbiol. Immunol. 45:801-811.
137. Ryll, R., K. Watanabe, N. Fujiwara, H. Takimoto, R. Hasunuma, Y. Kumazawa, M. Okada, and I. Yano. 2001. Mycobacterial cord factor, but not sulfolipid, causes depletion of NKT cells and upregulation of CD1d1 on murine macrophages. Microbes Infect. 3:611-619.
138. Sambandamurthy, V. K., S. C. Derrick, K. V. Jalapathy, B. Chen, R. G. Russell, S. L. Morris, and W. R. Jacobs, Jr. 2005. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun. 73:1196-1203.
139. Sampson, S. L., C. C. Dascher, V. K. Sambandamurthy, R. G. Russell, W. R. Jacobs, Jr., B. R. Bloom, and M. K. Hondalus. 2004. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect. Immun. 72:3031-3037.
140. Schaible, U. E., and S. H. Kaufmann. 2000. CD1 molecules and CD1-dependent T cells in bacterial infections: a link from innate to acquired immunity? Semin. Immunol. 12:527-535.
141. Schaible, U. E., S. Sturgill-Koszycki, P. H. Schlesinger, and D. G. Russell. 1998. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J. Immunol. 160:1290-1296.
142. Seah, G. T., and G. A. Rook. 2001. High levels of mRNA encoding IL-4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested reverse transcriptase-polymerase chain reaction; correlations with serum IgE levels. Scand. J. Infect. Dis. 33:106-109.
143. Seah, G. T., G. M. Scott, and G. A. Rook. 2000. Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J. Infect. Dis. 181:385-389.
144. + T cells participate in the memory immune response to Mycobacterium tuberculosis. Infect. Immun. 69:4320-4328.
145. + T cells to gamma interferon production in human tuberculosis. Infect. Immun. 69:3497-3501.
146. Sherman, D. R., M. Voskuil, D. Schnappinger, R. Liao, M. I. Harrell, and G. K. Schoolnik. 2001. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc. Natl. Acad. Sci. USA 98:7534-7539.
147. Shi, L., Y. J. Jung, S. Tyagi, M. L. Gennaro, and R. J. North. 2003. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc. Natl. Acad. Sci. USA 100:241-246.
148. Shiloh, M. U., and C. F. Nathan. 2000. Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria. Curr. Opin. Microbiol. 3:35-42.
149. Siebenmann, C. O. 1951. Effect of BCG vaccination and chemotherapy on experimental tuberculosis in mice. J. Immunol. 67:137-149.
150. Singh, K. K., X. Zhang, A. S. Patibandla, P. Chien, Jr., and S. Laal. 2001. Antigens of Mycobacterium tuberculosis expressed during preclinical tuberculosis: serological immunodominance of proteins with repetitive amino acid sequences. Infect. Immun. 69:4185-4191.
151. Skeiky, Y. A., M. R. Alderson, P. J. Ovendale, J. A. Guderian, L. Brandt, D. C. Dillon, A. Campos-Neto, Y. Lobet, W. Dalemans, I. M. Orme, and S. G. Reed. 2004. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J. Immunol. 172:7618-7628.
152. Skjot, R. L., I. Brock, S. M. Arend, M. E. Munk, M. Theisen, T. H. Ottenhoff, and P. Andersen. 2002. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the ESAT-6 gene family. Infect. Immun. 70:5446-5453.
153. Smith, D. W. 1985. Protective effect of BCG in experimental tuberculosis. Adv. Tuberc. Res. 22:1-97.
154. Smith, P. G. 1994. BCG vaccination, p. 297-310. In P. D. O. Davies (ed.), Clinical tuberculosis, 1st ed. Chapman and Hall Medical, London, England.
155. Sorensen, A. L., S. Nagai, G. Houen, P. Andersen, and A. B. Andersen. 1995. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 63:1710-1717.
156. Sousa, A. O., R. J. Mazzaccaro, R. G. Russell, F. K. Lee, O. C. Turner, S. Hong, L. Van Kaer, and B. R. Bloom. 2000. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Proc. Natl. Acad. Sci. USA 97:4204-4208.
157. Stenger, S. 2001. Cytolytic T cells in the immune response to mycobacterium tuberculosis. Scand. J. Infect. Dis. 33:483-487.
158. Stenger, S., and R. L. Modlin. 2002. Control of Mycobacterium tuberculosis through mammalian Toll-like receptors. Curr. Opin. Immunol. 14:452-457.
159. Sterne, J. A., L. C. Rodrigues, and I. N. Guedes. 1998. Does the efficacy of BCG decline with time since vaccination? Int. J. Tuberc. Lung Dis. 2:200-207.
160. Stokes, R. W., R. Norris-Jones, D. E. Brooks, T. J. Beveridge, D. Doxsee, and L. M. Thorson. 2004. The glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages. Infect. Immun. 72:5676-5686.
161. Sturgill-Koszycki, S., P. H. Schlesinger, P. Chakraborty, P. L. Haddix, H. L. Collins, A. K. Fok, R. D. Allen, S. L. Gluck, J. Heuser, and D. G. Russell. 1994. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263:678-681.
162. Sugawara, I., T. Udagawa, S. C. Hua, M. Reza-Gholizadeh, K. Otomo, Y. Saito, and H. Yamada. 2002. Pulmonary granulomas of guinea pigs induced by inhalation exposure of heat-treated BCG Pasteur, purified trehalose dimycolate and methyl ketomycolate. J. Med. Microbiol. 51:131-137.
163. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor I in mediating immune response to microbial lipoproteins. J. Immunol. 169:10-14.
164. Tiberio, L., L. Fletcher, J. H. Eldridge, and D. D. Duncan. 2004. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine 22:1515-1523.
165. Ting, L. M., A. C. Kim, A. Cattamanchi, and J. D. Ernst. 1999. Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163:3898-3906.
166. Tufariello, J. M., W. R. Jacobs, Jr., and J. Chan. 2004. Individual Mycobacterium tuberculosis resuscitation-promoting factor homologues are dispensable for growth in vitro and in vivo. Infect. Immun. 72:515-526.
167. Turner, J., T. Corrah, S. Sabbally, H. Whittle, and H. M. Dockrell. 2000. A longitudinal study of in vitro IFNgamma production and cytotoxic T-cell responses of tuberculosis patients in the Gambia. Tuberc. Lung Dis. 80:161-169.
168. Turner, J., E. R. Rhoades, M. Keen, J. T. Belisle, A. A. Frank, and I. M. Orme. 2000. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect. Immun. 68:1706-1709.
169. Turner, O. C., A. D. Roberts, A. A. Frank, S. W. Phalen, D. M. McMurray, J. Content, O. Denis, S. D'Souza, A. Tanghe, K. Huygen, and I. M. Orme. 2000. Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infect. Immun. 68:3674-3679.
170. Ulrich, J. T., and K. R. Myers. 1995. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 6:495-524.
171. Ulrichs, T., D. B. Moody, E. Grant, S. H. Kaufmann, and S. A. Porcelli. 2003. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect. Immun. 71:3076-3087.
172. Ulrichs, T., and S. A. Porcelli. 2000. CD1 proteins: targets of T-cell recognition in innate and adaptive immunity. Rev. Immunogenet. 2:416-432.
173. Underbill, D. M., A. Ozinsky, K. D. Smith, and A. Aderem. 1999. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc. Natl. Acad. Sci. USA 96:14459-14463.
174. van Crevel, R., E. Karyadi, F. Preyers, M. Leenders, B. J. Kullberg, R. H. Nelwan, and J. W. van der Meer. 2000. Increased production of interleukin 4 by CD4+ and CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities. J. Infect. Dis. 181:1194-1197.
175. van Pinxteren, L. A., J. P. Cassidy, B. H. Smedegaard, E. M. Agger, and P. Andersen. 2000. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30:3689-3698.
176. van Pinxteren, L. A. H., P. Ravn, E. M. Agger, J. M. Pollock, and P. Andersen. 2000. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin. Diagn. Lab Immunol. 7:155-160.
177. Vekemans, J., C. Lienhardt, J. S. Sillah, J. G. Wheeler, G. P. Lahai, M. T. Doherty, T. Corrah, P. Andersen, K. P. McAdam, and A. Marchant. 2001. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in the Gambia. Infect. Immun. 69:6554-6557.
178. Vergne, I., J. Chua, and V. Deretic. 2003. Tuberculosis toxin blocking phagosome maturation inhibits a novel Ca2+/calmodulin-PI3K hVPS34 cascade. J Exp. Med. 198:653-659.
179. Vergne, I., R. A. Fratti, P. J. Hill, J. Chua, J. Belisle, and V. Deretic. 2004. Mycobacterium tuberculosis phagosome maturation arrest: mycobacterial phosphatidylinositol analog phosphatidylinositol mannoside stimulates early endosomal fusion. Mol. Biol. Cell 15:751-760.
180. Vogels, R., D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M. P. de Bethune, S. Kostense, G. Penders, N. Helmus, W. Koudstaal, M. Cecchini, A. Wetterwald, M. Sprangers, A. Lemckert, O. Ophorst, B. Koel, M. van Meerendonk, P. Quax, L. Panitti, J. Grimbergen, A. Bout, J. Goudsmit, and M. Havenga. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77:8263-8271.
181. Vordermeier, H. M., M. A. Chambers, P. J. Cockle, A. O. Whelan, J. Simmons, and R. G. Hewinson. 2002. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun. 70:3026-3032.
182. Voskuil, M. I., D. Schnappinger, K. C. Visconti, M. I. Harrell, G. M. Dolganov, D. R. Sherman, and G. K. Schoolnik. 2003. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp. Med. 198:705-713.
183. Wagner, D., J. Maser, B. Lai, Z. Cai, C. E. Barry, 3rd, K. Honer Zu Bentrup, D. G. Russell, and L. E. Bermudez. 2005. Elemental analysis of Mycobacterium avium-, Mycobacterium tuberculosis-, and Mycobacterium smegmatis-containing phagosomes indicates pathogen-induced microenvironments within the host cell's endosomal system. J. Immunol. 174:1491-1500.
184. Walburger, A., A. Koul, G. Ferrari, L. Nguyen, C. Prescianotto-Baschong, K. Huygen, B. Klebl, C. Thompson, G. Bacher, and J. Pieters. 2004. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science 304:1800-1804.
185. Weinrich Olsen, A., L. A. van Pinxteren, L. Meng Okkels, P. Birk Rasmussen, and P. Andersen. 2001. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect. Immun. 69:2773-2778.
186. Welsh, M. D., R. T. Cunningham, D. M. Corbett, R. M. Girvin, J. McNair, R. A. Skuce, D. G. Bryson, and J. M. Pollock. 2005. Influence of pathological progression on the balance between cellular and humoral immune responses in bovine tuberculosis. Immunology 114:101-111.
187. Wiart, A., A. Jepson, W. Banya, S. Bennett, H. Whittle, N. G. Martin, and A. V. Hill. 2004. Quantitative association tests of immune responses to antigens of Mycobacterium tuberculosis: a study of twins in West Africa. Twin Res. 7:578-588.
188. Williams, A., G. J. Hatch, S. O. Clark, K. E. Gooch, K. A. Hatch, G. A. Hall, K. Huygen, T. H. Ottenhoff, K. L. Franken, P. Andersen, T. M. Doherty, S. H. Kaufmann, L. Grode, P. Seiler, C. Martin, B. Gicquel, S. T. Cole, P. Brodin, A. S. Pym, W. Dalemans, J. Cohen, Y. Lobet, N. Goonetilleke, H. McShane, A. Hill, T. Parish, D. Smith, N. G. Stoker, D. B. Lowrie, G. Kallenius, S. Svenson, A. Pawlowski, K. Blake, and P. D. Marsh. 2005. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinburgh) 85:29-38.
189. Wilson, M. E., H. V. Fineberg, and G. A. Colditz. 1995. Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clin. Infect. Dis. 20:982-991.
190. Winau, F., S. H. Kaufmann, and U. E. Schaible. 2004. Apoptosis paves the detour path for CD8 T-cell activation against intracellular bacteria. Cell. Microbiol. 6:599-607.
191. Yeremeev, V. V., T. K. Kondratieva, E. I. Rubakova, S. N. Petrovskaya, K. A. Kazarian, M. V. Telkov, S. F. Biketov, A. S. Kaprelyants, and A. S. Apt. 2003. Proteins of the Rpf family: immune cell reactivity and vaccination efficacy against tuberculosis in mice. Infect. Immun. 71:4789-4794.
192. Yeremeev, V. V., I. V. Lyadova, B. V. Nikonenko, A. S. Apt, C. Abou-Zeid, J. Inwald, and D. B. Young. 2000. The 19-kD antigen and protective immunity in a murine model of tuberculosis. Clin. Exp. Immunol. 120:274-279.
193. Yuan, Y., D. D. Crane, and C. E. Barry 3rd. 1996. Stationary-phase- associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J. Bacteriol. 178:4484-4492.
194. Yuan, Y., D. D. Crane, R. M. Simpson, Y. Q. Zhu, M. J. Hickey, D. R. Sherman, and C. E. Barry 3rd. 1998. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc. Natl. Acad. Sci. USA 95:9578-9583.
195. Ziv, E., C. L. Daley, and S. Blower. 2004. Potential public health impact of new tuberculosis vaccines. Emerg. Infect. Dis. 10:1529-1535.